Academic literature on the topic 'Francesco Maria Balbi'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Francesco Maria Balbi.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Francesco Maria Balbi"

1

Colombo Timelli, Maria. "Anna Maria Babbi, Il romanzo francese del Quattrocento: ‘Pierre de Provence’ e dintorni." Studi Francesi, no. 147 (XLX | III) (December 1, 2005): 614–15. http://dx.doi.org/10.4000/studifrancesi.32812.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bissell, L. A., D. Furst, S. Johnson, et al. "POS0868 THE DEVELOPMENT OF THE LINEAR CRISS; A CLINICAL AND PATIENT MEANINGFUL ANCHOR TO THE ACR-CRISS IN SCLERODERMA." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 728. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1896.

Full text
Abstract:
BackgroundThe ACR Composite Response Index in Systemic Sclerosis (ACR-CRISS) is one of the first composite outcome measures in diffuse cutaneous Systemic sclerosis (dcSSc).1 It relies on validated clinical domains selected through a data-driven methodology; however, it only provides a probability of response and is unable to differentiate between patients who do not improve and who worsen respectively.ObjectivesTo improve the clinical interpretation of the ACR-CRISS by creating a continuous ranked score of clinically and patient meaningful changes of its individual measures.MethodsFollowing Om
APA, Harvard, Vancouver, ISO, and other styles
3

Elhai, M., M. Boubaya, N. Sritharan, et al. "POS0140 PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 297.1–297. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1224.

Full text
Abstract:
BackgroundRisk-stratification is key in a heterogeneous disease like systemic sclerosis (SSc). Until now, SSc patients are stratified according to the extent of skin involvement into limited cutaneous, diffuse cutaneous and sine scleroderma subtypes. However, this classification remains inaccurate to capture disease heterogeneity. Autoantibodies are found in more than 90% of the patients and can be detected before onset of the disease. Among them, three predominant and specific antibodies are used: anti-centromere, anti-Scl70 and RNA polymerase III antibodies.ObjectivesTo compare the performan
APA, Harvard, Vancouver, ISO, and other styles
4

Bruni, C., L. Tofani, H. Fretheim, et al. "OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 157.2–159. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2018.

Full text
Abstract:
BackgroundPre-capillary pulmonary hypertension (precapPH) affects 9-15% of patients with systemic sclerosis (SSc) and may be associated with interstitial lung disease (ILD) of variable extent.Immunosuppressants (IMS) are standard of care for treating ILD, skin or musculoskeletal manifestations in SSc. However, their beneficial effect on precapPH remains unclear.ObjectivesTo determine whether exposure to IMS in SSc-precapPH affects morbidity and mortality in the EUSTAR cohort.MethodsIn the approved EUSTAR project CP111, we included SSc patients with precapPH (mPAP ≥21 mmHg, PWP ≤15 mmHg, PVR ≥2
APA, Harvard, Vancouver, ISO, and other styles
5

Ravaioli, Sara, Roberta Maltoni, Elisabetta Petracci, et al. "Abstract P2-13-44: HDAC6 is an unfavorable prognostic factor in HER2-positive breast cancer patients treated with adjuvant trastuzumab." Cancer Research 82, no. 4_Supplement (2022): P2–13–44—P2–13–44. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-13-44.

Full text
Abstract:
Abstract Background Trastuzumab is the cornerstone of adjuvant therapy for HER2-positive breast cancer (BC), but due to de novo or primary resistance, >20% of early-stage patients become resistant. Thus, predicting the mechanisms of trastuzumab resistance would facilitate the planning of specific therapeutic strategies. We performed a case-control study of 26 HER2-positive BC patients who relapsed within 5 years of starting adjuvant treatment and 26 controls, no relapsed, analyzing an extensive gene expression profile. Methods Total RNA was isolated from formalin-fixed paraffin-embedded
APA, Harvard, Vancouver, ISO, and other styles
6

Italian network, The Rehabilitation Complexity Scale for respiratory patients. "The ability of the Rehabilitation Complexity Scale (RCS) to capture disability in respiratory patients admitted for in-hospital rehabilitation." Monaldi Archives for Chest Disease, November 21, 2023. http://dx.doi.org/10.4081/monaldi.2023.2732.

Full text
Abstract:
The aim of this pilot retrospective study was to test the Rehabilitation complexity scale (RCS-E v13) in patients from 15 Italian pulmonary rehabilitation (PR) units and correlate RCS-E v13 to the most used clinical and functional outcome measures. At admission and discharge, clinical data [comorbidities with the Cumulative Illness Rating Scale (CIRS)], Barthel Index (BI), Barthel Index dyspnea (BI-d), COPD Assessment Test (CAT), and six-minute walking test (6MWT) were collected, and RCS-E total score calculated. Two-hundred nineteen patients [30.6% COPD, 43.4% chronic respiratory failure (CRF
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Francesco Maria Balbi"

1

Le Tentazioni di Sant'Antonio abate: Arte e letteratura. Scalpendi editore, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!